Lacosamid Zentiva (Lacosamide)

Lacosamide is an antiepileptic drug that acts on voltage‑gated sodium channels to control seizure activity.

• Partial‑onset seizures: reduces seizure frequency as an adjunct therapy in epilepsy patients.
• Focal seizures: improves seizure control when added to existing antiepileptic regimens.
• Refractory epilepsy: offers an alternative mechanism for patients not responding adequately to other medications.

• Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing the inactive state of these channels, it diminishes repetitive neuronal firing, thereby reducing the propagation of epileptic discharges without significantly affecting normal neuronal activity.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Fatigue: increased tiredness or lack of energy.
• Nausea: mild to moderate stomach upset.
• Diplopia: occasional double vision.
• Headache: mild to moderate pain in the head.
• Somnolence: tendency to feel sleepy.

Serious or Rare Side Effects

• Suicidal ideation: emergence of thoughts of self‑harm.
• Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hypersensitivity: rash, angioedema, or anaphylaxis.
• Liver enzyme elevation: significant increase in hepatic transaminases.
• Blood dyscrasias: rare cases of agranulocytosis or thrombocytopenia.

When prescribing Lacosamid Zentiva, clinicians should consider several safety measures.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Cardiac conduction: obtain baseline ECG and watch for PR‑interval changes.
• Pregnancy: risk category unknown; avoid unless benefits outweigh potential risks.
• Concomitant antiepileptics: monitor for additive CNS depression.
• Store at ambient temperature: keep in the original container, protect from moisture.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
• Drugs that prolong PR interval (e.g., quinidine, amiodarone): increase risk of cardiac conduction disturbances.

Moderate Interactions (Monitor Closely)

• Other antiepileptic drugs: may enhance central nervous system side‑effects.
• Oral contraceptives: lacosamide may reduce contraceptive efficacy; consider additional protection.
• Alcohol: combined use can intensify sedation and dizziness.